Alvocidib (INN; also known as flavopiridol) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development by Tolero Pharmaceuticals for the treatment of acute myeloid leukemia.

[2] The target of alvocidib is the positive transcription elongation factor P-TEFb.

[3][4] Treatment of cells with alvocidib leads to inhibition of P-TEFb and the loss of mRNA production.

[5][6] The compound is a synthetic analog of natural product rohitukine which was initially extracted from Aphanamixis polystachya (formerly Amoora rohituka, hence the name) and later from Dysoxylum binectariferum.

[7][8] The FDA has granted orphan drug designation to alvocidib for the treatment of patients with acute myeloid leukemia.